---
title: "FICT vs ELISA vs PCR: A Method Comparison for Veterinary Diagnostics"
date: 2026-08-13
description: "Head-to-head comparison of fluorescence immunochromatography (FICT), ELISA, and PCR for veterinary diagnostics — sensitivity, time-to-result, cost, quantitation, and best-fit clinical scenarios."
---

# FICT vs ELISA vs PCR: A Method Comparison

## 1. Scope

Veterinary diagnosticians face a recurring choice: which test technology fits a given clinical scenario. This comparison evaluates the three dominant immunoassay/molecular methods — **FICT** (fluorescence immunochromatography), **ELISA** (enzyme-linked immunosorbent assay), and **PCR** (polymerase chain reaction) — across the dimensions that matter in practice.

| Dimension | FICT | ELISA | PCR |
|-----------|------|-------|-----|
| Analyte | Protein / antigen / antibody | Protein / antigen / antibody | Nucleic acid (DNA/RNA) |
| Readout | Fluorescence (quantitative) | Absorbance (quantitative) | Amplification (qualitative / semi-quant) |
| Time to result | 3–15 min | 1–4 h | 1–4 h |
| Throughput | 1–6 / run, on-site | Batch, lab | Batch, lab |
| Quantitation | Yes (concentration) | Yes (concentration) | Mostly qualitative (Ct) |
| LOD | pg/ml | pg/ml | < 10 copies |
| Equipment | Compact analyzer | Plate reader | Thermal cycler |
| Operator | Minimal training | Trained tech | Trained tech |

---

## 2. Sensitivity & Analytical Performance

| Metric | FICT | ELISA | PCR |
|--------|------|-------|-----|
| Analytical sensitivity | pg/ml | pg/ml | Attomolar |
| Dynamic range | 3–4 logs | 2–3 logs | 6–8 logs (Ct) |
| Intra-assay CV% | < 8% | < 10% | < 5% (Ct) |
| Correlation (FICT vs ELISA) | r > 0.95 | — | — |

FICT matches ELISA for protein-analyte sensitivity while being instrument-read at the point of care. PCR exceeds both in sensitivity for **nucleic acid** targets, but is not a substitute for protein biomarkers (CRP, SDMA, hormones) where the analyte is a protein, not DNA.

---

## 3. Time-to-Result & Clinical Workflow

The decisive advantage of FICT is **turnaround time**:

```
ELISA:  sample → lab → batch → 1–4 h → result
PCR:    sample → lab → extraction → amplification → 1–4 h → result
FICT:   sample → analyzer → 3–15 min → result (same visit)
```

For time-sensitive decisions — acute inflammation (CRP/SAA), heart failure (NT-proBNP), breeding timing (progesterone) — same-visit results change treatment decisions the same day.

---

## 4. Cost per Test

| Method | Instrument cost | Consumable cost | Total cost per reportable result |
|--------|----------------|-----------------|----------------------------------|
| FICT | Moderate (analyzer) | Low–moderate | **Low** |
| ELISA | High (reader + washer) | Moderate | Moderate |
| PCR | High (cycler + reagents) | High | **High** |

FICT's bundled analyzer + assay model amortizes well in high-volume clinics, making it the lowest cost-per-reportable-result for routine protein biomarkers.

---

## 5. Best-Fit Clinical Scenarios

| Scenario | Recommended | Rationale |
|----------|-------------|-----------|
| Acute inflammation (canine CRP) | **FICT** | Quantitative, same-visit |
| Early kidney disease (SDMA) | **FICT** | Quantitative, longitudinal monitoring |
| Heart failure staging (NT-proBNP) | **FICT** | Quantitative, same-visit |
| Viral antigen (CPV/FeLV) | FICT or PCR | Antigen → FICT; confirm/NA → PCR |
| Pathogen ID (which virus) | **PCR** | Nucleic-acid specificity |
| Hormone profiling (T4/cortisol) | FICT or ELISA | Quantitative, FICT faster |

---

## 6. Conclusion

For **protein biomarkers and infectious-disease antigens**, FICT delivers ELISA-grade quantitative performance with POCT turnaround — the optimal balance for clinical veterinary practice. PCR remains the reference for **nucleic-acid confirmation** and pathogen identification where protein assays are not applicable.

*For underlying technology, see the [FICT Technical White Paper](/fict-technology/fluorescence-immunochromatography/). For assay-level performance numbers, see the [Data Hub](https://data.migibio.com/assay-performance/).*
